Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
23. Mai 2023 06:15 ET
|
Affimed N.V.
Phase 2 combination study of AFM13 with AB-101 in relapsed or refractory (r/r) classical Hodgkin Lymphoma (cHL) will be an open-label, multi-center, multi-cohort study with a safety run-in followed by...
Affimed Announces Annual General Meeting of Shareholders
22. Mai 2023 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, May 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
16. Mai 2023 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
11. Mai 2023 10:05 ET
|
Affimed N.V.
A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory (r/r) peripheral T cell lymphoma (PTCL) is accepted as a poster presentationA trial in progress abstract...
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
26. April 2023 10:00 ET
|
Affimed N.V.
AFM24-101 phase 1/2 interim results from the non-small cell lung cancer cohort accepted for poster presentationAFM24-101 phase1/2 interim results from the colorectal cancer cohort accepted for online...
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
17. April 2023 16:05 ET
|
Affimed N.V.
The poster presentation highlights the relevance of CD16A shedding for serial killing by AFM13-engaged natural killer (NK) cellsIt demonstrates the potential of AFM13 to induce serial killing, even in...
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
16. April 2023 15:00 ET
|
Affimed N.V.
AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in Intent to Treat (ITT) populationPatients with...
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
06. April 2023 16:05 ET
|
Affimed N.V.
HEIDELBERG, Germany, April 06, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
29. März 2023 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Reports 2022 Financial Results and Operational Progress
23. März 2023 06:30 ET
|
Affimed N.V.
AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meetingAFM24:...